Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Omthera Pharmaceuticals

- PMLiVE

Roche and AZ claim FDA breakthrough status for new drugs

Designation could speed up development for Roche’s ocrelizumab and AZ’s durvalumab 

- PMLiVE

AZ cancer immunotherapy combo impresses in lung cancer trial

Durvalumab and tremelimumab combination show 'encouraging' efficacy signs

- PMLiVE

AstraZeneca wins European approval for Tagrisso

The first-in-class lung cancer treatment receives a conditional licence

- PMLiVE

Pharma trio join with top universities for new drug search

AZ, GSK and J&J join forces with Imperial, University College and Cambridge

EU flag

Nine positive opinions for new drugs at CHMP meeting

Tagrisso, Zurampic and Portrazza among the latest recommendations

- PMLiVE

AZ takes majority stake in cancer drug developer Acerta

Will pay $4bn for a 55% share in the Dutch biopharma company

China flag thumb

AstraZeneca sets sights on China with Takeda deal

Buys the Japanese firm's respiratory drugs to extends their ongoing biologics R&D collaboration

- PMLiVE

AZ confirms interest in Acerta takeover

Possible acquisition of Netherlands-based cancer drug developer may be worth more than $5bn

- PMLiVE

NICE changes stance on AZ’s Lynparza after concessions

NHS patients in England and Wales to get ovarian cancer drug

- PMLiVE

UK patients get early access to AZ’s lung cancer drug Tagrisso

The treatment is the fourth made available under the EAMS

Sanofi reception

Sanofi and AstraZeneca agree massive compound swap deal

Will exchange over 200,000 compounds in a new open innovation collaboration

- PMLiVE

AZ sets price of new lung cancer drug Tagrisso

Price tag of $150,000 per year given

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links